MedTrace Logo

Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

NCT00387270 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2008-01-04

No results posted yet for this study

Summary

This study is being conducted to determine the safety and tolerability of Dimebon in people with Huntington's disease after short-term exposure (one week) and after longer exposure (three months). Also, the study will assess whether or not there is an effect of Dimebon on the symptoms of Huntington's disease, including cognitive (thinking abilities), motor (movement), behavior, and overall functioning.

Conditions

Interventions

DRUG

Dimebon

Dimebon 10 or 20 mg TID x 7 days

Sponsors & Collaborators

  • Huntington Study Group

    collaborator NETWORK

  • Medivation, Inc.

    lead INDUSTRY

Principal Investigators

  • Karl D Kieburtz, MD · University of Rochester Medical School, Huntington Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-03-31
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387270 on ClinicalTrials.gov